Drug Type Small molecule drug |
Synonyms LB-1.2, LB-102, homologue of LB-100 |
Mechanism 5-HT7 receptor antagonists(Serotonin 7 (5-HT7) receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists), D3 receptor antagonists(Dopamine D3 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H26N2O6 |
InChIKeyQJMAFHBXQNFFKL-UHFFFAOYSA-N |
CAS Registry1047659-23-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Phase 1 | US | LB Pharmaceuticals, Inc.Startup | 22 Jan 2020 |
NCT04187560 (Pubmed) Manual | Phase 1 | 64 | (SAD portion) | yngplnusml(pkcgbikpse) = LB-102 was generally safe and well-tolerated, and clinical lab values were unremarkable at all doses, save for prolactin which was transiently elevated in the majority of subjects treated with LB-102 fzarpucklt (uwxisjfzyc ) | Positive | 16 Jul 2022 | |
(MAD portion) | |||||||
Phase 1 | - | 64 | panaxrwypj(rmukauqwon) = consistent with dopamine antagonists and included transient increases in QT interval and prolactin levels, though these did not result in clinical observations yffbsrzjns (kdahayyvsk ) View more | Positive | 14 Sep 2020 |